- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06075953
DCIS: PRZEkształcenie próbne dotyczące raka przewodowego in situ: ponowna ocena warunków przydatności aktywnego nadzoru w leczeniu
DCIS: Badanie RECAST – rak przewodowy in situ: ponowna ocena warunków przydatności aktywnego nadzoru w leczeniu: pilotażowe badanie dotyczące zapobiegania rakowi piersi
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease.
Participants will be asked to receive control hormonal therapy or an investigational hormonal therapy treatment. Participants will be asked to return for evaluation with MRI at three months and six months. Depending on the evaluation participants will have the option to continue on the treatment. If the evaluation suggests surgery is recommended, the participant will discontinue the study treatment and will undergo surgery. In addition to the treatment and MRI evaluation, participants will be asked to provide blood sample to understand their immune status, provide saliva sample for genetic testing, provide the study with a portion of the tissue or slides generated from tissue removed during surgery performed as part of their standard of care.
Przegląd badań
Status
Warunki
Szczegółowy opis
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with Ductal cell Carcinoma In Situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. The current management of most patients with DCIS involves surgical intervention with or without radiation, similar to more aggressive breast cancers. These treatments can come with some significant health effects.The main question this study aims to answer is: to determine whether novel endocrine therapy increases the fraction of patients who will be suitable for long-term active surveillance.
Participants will be asked to take one of three investigational study medication (z-Elacestrant, Testosterone + Anastrazole, or Endoxifen) or receive control hormonal therapy (Tamoxifen or an aromatase inhibitor), depending on the treatment to which they have been randomized. Participants will be asked to return for evaluation with MRI at three months and six months. Depending on the evaluation, participants will have the option to continue on the treatment, with follow up evaluations of Mammogram and MRI at 6 month intervals. If the evaluation suggests surgery is recommended, the participant will discontinue the study treatment and will undergo surgery. In addition to the treatment and MRI evaluation, participants will be asked to:
- Provide blood sample to understand their immune status
- Provide saliva sample for genetic testing
- Provide the study with a portion of the tissue or slides generated from tissue removed during surgery performed as part of their standard of care.
Participants will be followed annually for 10 years.
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 2
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Tammy Neseth, MA, CCRP
- Numer telefonu: +1 (507) 269-8060
- E-mail: t.neseth@qlhc.org
Kopia zapasowa kontaktu do badania
- Nazwa: Sabrina Mayhew, Ph.D. Nursing
- Numer telefonu: +1 (888) 282-7099
- E-mail: s.mayhew@qlhc.org
Lokalizacje studiów
-
-
California
-
Berkeley, California, Stany Zjednoczone, 94158
- Rekrutacyjny
- Berkeley Outpatient Center
-
Kontakt:
- Niloufar Abdollahi
- Numer telefonu: 415.476.3322
- E-mail: Niloufar.abdollahi@ucsf.edu
-
Główny śledczy:
- Jordan Jackson, MD
-
Kontakt:
- Dasha Peiris
- Numer telefonu: 415-533-0141
- E-mail: Dasha.Peiris@ucsf.edu
-
Duarte, California, Stany Zjednoczone, 91010
- Rekrutacyjny
- City of Hope -Duarte Cancer Center
-
Główny śledczy:
- Jennifer Tseng, MD
-
Kontakt:
- Mellissa Henry, RN, MSN, FNP-C
- Numer telefonu: 626-713-8895
- E-mail: mehenry@coh.org
-
Irvine, California, Stany Zjednoczone, 92618
- Rekrutacyjny
- City of Hope - Lennar Foundation Cancer Center
-
Główny śledczy:
- Jennifer Tseng, MD
-
Kontakt:
- Mellissa Henry, RN, MSN, FNP-C
- Numer telefonu: 626-713-8895
- E-mail: mehenry@coh.org
-
Los Angeles, California, Stany Zjednoczone, 90095
- Rekrutacyjny
- UCLA
-
Kontakt:
- Sophia Quiroz, Clinical Research Coordinator
- Numer telefonu: 310-794-0130
- E-mail: SQuiroz@mednet.ucla.edu
-
Główny śledczy:
- Mediget Teshome, MD
-
San Francisco, California, Stany Zjednoczone, 94158
- Rekrutacyjny
- UCSF
-
Główny śledczy:
- Jordan Jackson, MD
-
Kontakt:
- Dasha Peiris
- Numer telefonu: 415-533-0141
- E-mail: Dasha.Peiris@ucsf.edu
-
South Pasadena, California, Stany Zjednoczone, 91030
- Rekrutacyjny
- City of Hope
-
Główny śledczy:
- Jennifer Tseng, MD
-
Kontakt:
- Mellissa Henry, RN, MSN, FNP-C
- Numer telefonu: 626-713-8895
- E-mail: mehenry@coh.org
-
Walnut Creek, California, Stany Zjednoczone, 94598
- Rekrutacyjny
- John Muir Health
-
Kontakt:
- Jen Johnson, Clinical Research Coordinator
- Numer telefonu: 925-674-2580
- E-mail: Jen.Johnson@johnmuirhealth.com
-
Główny śledczy:
- Monica Eigelberger, MD
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stany Zjednoczone, 20010
- Rekrutacyjny
- MedStar Washington Hospital Center
-
Główny śledczy:
- Marc Boisvert, MD
-
Kontakt:
- Hiwot Guebre-Xabiher, Research Manager
- Numer telefonu: 202-877-8839
- E-mail: Hiwot.Guebre-Xabiher@medstar.net
-
-
Florida
-
Tampa, Florida, Stany Zjednoczone, 33612
- Rekrutacyjny
- Moffitt Cancer Center
-
Kontakt:
- Neveen Abdo, Clinical Research Coordinator
- Numer telefonu: 727-748-9345
- E-mail: Neveen.abdo@moffitt.org
-
Główny śledczy:
- Laura Kruper, MD
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30322
- Rekrutacyjny
- Winship Cancer Institute, Emory University
-
Główny śledczy:
- Clara Farley, MD
-
Kontakt:
- Winship Clinical Trials Office
- Numer telefonu: 1-404-778-1868
- E-mail: winshipcto@emory.edu
-
Kontakt:
- Trisha Burrello
- E-mail: trisha.n.burrello@emory.edu
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60637
- Rekrutacyjny
- University of Chicago Medical Center
-
Kontakt:
- Vhenyse Encarnacion
- E-mail: vhenyse.encarnacion@bsd.uchicago.edu
-
Główny śledczy:
- Betty Fan, MD
-
-
Minnesota
-
Maple Grove, Minnesota, Stany Zjednoczone, 55369
- Rekrutacyjny
- Maple Grove Cancer Center
-
Kontakt:
- Oncology Access Nurse
- Numer telefonu: 612-624-2620
- E-mail: ccinfo@umn.edu
-
Główny śledczy:
- Jane Hui, MD
-
Minneapolis, Minnesota, Stany Zjednoczone, 55455
- Rekrutacyjny
- University of Minnesota
-
Kontakt:
- Oncology Access Nurse
- Numer telefonu: 612-624-2620
- E-mail: ccinfo@umn.edu
-
Główny śledczy:
- Jane Hui, MD
-
Minneapolis, Minnesota, Stany Zjednoczone, 55404
- Rekrutacyjny
- Hennepin Healthcare -Minneapolis
-
Kontakt:
- Hannah Merrill
- Numer telefonu: 952-993-0996
- E-mail: hannah.merrill@parknicollet.com
-
Kontakt:
- Niki Hoese
- Numer telefonu: 952-993-1585
- E-mail: nicole.hoese@parknicollet.com
-
Główny śledczy:
- Satya Bommakanti, MD
-
Saint Louis Park, Minnesota, Stany Zjednoczone, 55426
- Rekrutacyjny
- Health Partners - Frauenshuh Cancer Center
-
Kontakt:
- Hannah Merrill
- Numer telefonu: 952-993-0996
- E-mail: hannah.merrill@parknicollet.com
-
Kontakt:
- Niki Hoese
- Numer telefonu: 952-993-1585
- E-mail: nicole.hoese@parknicollet.com
-
Główny śledczy:
- Rachel Lerner, MD
-
Saint Paul, Minnesota, Stany Zjednoczone, 55101
- Rekrutacyjny
- Health Partners - Regions Hospital
-
Kontakt:
- Hannah Merrill
- Numer telefonu: 952-993-0996
- E-mail: hannah.merrill@parknicollet.com
-
Kontakt:
- Niki Hoese
- Numer telefonu: 952-993-1585
- E-mail: nicole.hoese@parknicollet.com
-
Główny śledczy:
- Rachel Lerner, MD
-
-
New Jersey
-
Englewood, New Jersey, Stany Zjednoczone, 07631
- Rekrutacyjny
- Englewood Hospital and Medical Center
-
Kontakt:
- Kayla Williams
- Numer telefonu: 9786 201-894-3000
- E-mail: kayla.williams@ehmchealth.org
-
Główny śledczy:
- Jennifer Marti, MD
-
-
New York
-
New York, New York, Stany Zjednoczone, 10011
- Rekrutacyjny
- Mount Sinai Chelsea
-
Główny śledczy:
- Tara Balija, MD
-
Kontakt:
- Contact: Site Public Contact
- Numer telefonu: 212-824-7309
- E-mail: CRSU@mssm.edu
-
New York, New York, Stany Zjednoczone, 10029
- Rekrutacyjny
- Icahn School of Medicine at Mount Sinai
-
Główny śledczy:
- Tara Balija, MD
-
Kontakt:
- Contact: Site Public Contact
- Numer telefonu: 212-824-7309
- E-mail: CRSU@mssm.edu
-
New York, New York, Stany Zjednoczone, 10019
- Rekrutacyjny
- Mount Sinai West
-
Główny śledczy:
- Tara Balija, MD
-
Kontakt:
- Contact: Site Public Contact
- Numer telefonu: 212-824-7309
- E-mail: CRSU@mssm.edu
-
New York, New York, Stany Zjednoczone, 10003
- Rekrutacyjny
- Mount Sinai Union Square
-
Główny śledczy:
- Tara Balija, MD
-
Kontakt:
- Contact: Site Public Contact
- Numer telefonu: 212-824-7309
- E-mail: CRSU@mssm.edu
-
The Bronx, New York, Stany Zjednoczone, 10461
- Rekrutacyjny
- Montefiore Medical Center (Hutchinson Campus Tower 1)
-
Kontakt:
- Melissa Suarez
- Numer telefonu: 718-920-6742
- E-mail: mesuarez@montefiore.org
-
Główny śledczy:
- Sheldon Feldman, MD
-
Kontakt:
- Linda Castellanos
- Numer telefonu: 718-920-6742
- E-mail: lcastellan@montefiore.org
-
-
North Carolina
-
Durham, North Carolina, Stany Zjednoczone, 27710
- Rekrutacyjny
- Duke Cancer Institute
-
Kontakt:
- Breast Cancer Study Team
- Numer telefonu: 919-660-1278
- E-mail: breastcl@dm.duke.edu
-
Główny śledczy:
- Ton Wang, MD
-
Winston-Salem, North Carolina, Stany Zjednoczone, 27157
- Rekrutacyjny
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center
-
Główny śledczy:
- Marissa Howard-McNatt, MD
-
Kontakt:
- Brandy Baker and Lindsy Davis, RN
- Numer telefonu: 336-716-8941 OR 336-716-6748
- E-mail: brandy.baker@advocatehealth.org, lindsey.davis@advocatehealth.org
-
Kontakt:
- Sydney McEntire
- E-mail: sydney.mcentire@advocatehealth.org
-
-
Pennsylvania
-
Bryn Mawr, Pennsylvania, Stany Zjednoczone, 19010
- Aktywny, nie rekrutujący
- Bryn Mawr Hospital
-
Paoli, Pennsylvania, Stany Zjednoczone, 19301
- Aktywny, nie rekrutujący
- Paoli Hospital
-
Wynnewood, Pennsylvania, Stany Zjednoczone, 19096
- Aktywny, nie rekrutujący
- Lankenau Medical Center
-
-
Tennessee
-
Nashville, Tennessee, Stany Zjednoczone, 37232
- Rekrutacyjny
- Vanderbilt University Medical Center
-
Główny śledczy:
- Ingrid Meszoely, MD
-
Kontakt:
- Oncology nursing
- Numer telefonu: 1-800-811-8480
- E-mail: cip@vumc.org
-
Kontakt:
- Jennifer Goodman, RN, BSN
- Numer telefonu: 615.936.6825
- E-mail: jennifer.e.goodman@vumc.org
-
-
Utah
-
Salt Lake City, Utah, Stany Zjednoczone, 84112
- Rekrutacyjny
- Huntsman Cancer Institute
-
Główny śledczy:
- Kirstyn Brownson, MD
-
Kontakt:
- Janna Espinosa
- Numer telefonu: 801-585-0571
- E-mail: Janna.Espinosa@hci.utah.edu
-
-
Virginia
-
Richmond, Virginia, Stany Zjednoczone, 23298
- Rekrutacyjny
- Virginia Commonwealth University
-
Kontakt:
- Massey CTO Breast Team
- Numer telefonu: 804-628-6430
- E-mail: masseyctbrst@vcu.edu
-
Główny śledczy:
- Kandace McGuire, MD
-
-
Washington
-
Seattle, Washington, Stany Zjednoczone, 98109
- Rekrutacyjny
- Univesity of Washington (UW) / Fred Hutchinson Cancer Center (FHCC)
-
Główny śledczy:
- Sara Javid, MD
-
Kontakt:
- Sandra Mata-Diaz
- Numer telefonu: 206-221-3762
- E-mail: sandramd@uw.edu
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
A. Female, at least 18 years old
B. Previous diagnosis of HR+ DCIS (at least 50% ER or PR; biopsy will have been performed previously at diagnosis) with or without microinvasion
- Patients with a diagnosis of hormone positive DCIS who have undergone surgery with positive margins that have not been re-excised are candidates to enroll in the trial.
C. Patients who have previously received endocrine therapy should have a washout period of at minimum 4-6 weeks prior to the screening MRI on the RECAST-DCIS trial
D. Bilateral mammogram performed within up to 6 months (180 days) of the start of trial treatment may be used for screening evaluation. If a bilateral mammogram has been performed within 1 year (12 months) of the start of trial treatment, then a diagnostic unilateral mammogram within 6 months (180 days) of the start of trial treatment will be acceptable for screening evaluation.
E. MRI performed on an I SPY (RECAST) approved scanner within 2 months (60 days) of the start of trial treatment for lesion evaluation may be used for screening evaluation.
F. CBC w/ diff, CMP, and Lipid Panel within normal limits within a year of the start of trial treatment. Abnormal labs to be repeated within 60 days prior to the start of trial treatment. Patients will be considered eligible for screening labs that are abnormal or out-of-range if the investigator has deemed the lab results not-clinically significant
G. Negative urine or serum pregnancy test within 1 month of the start of trial treatment
H. Controlled HIV positive patients are allowed as long as their current medication does not contraindicate the study's investigational agent
I. Willingness and ability to provide tumor samples for research
Exclusion Criteria:
A. Pregnant or actively breastfeeding women
B. History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent based on review of the medical record and patient history
C. Invasive carcinoma or identification of a mass on MRI that is subsequently biopsied and found to be invasive cancer
D. Co-enrollment in clinical trials of pharmacologic agents requiring an IND
E. Ongoing treatment for DCIS other than what is specified in this protocol
F. Uncontrolled intercurrent illness, including psychiatric conditions, that would limit compliance with study requirements
G. Medical history or ongoing gastrointestinal disorders potentially affecting the absorption of investigational agent and/or tamoxifen. Active inflammatory bowel disease or chronic diarrhea, known active hepatitis A/B/C*, hepatic cirrhosis, short bowel syndrome, or any upper gastrointestinal surgery including gastric resection or banding procedures
*Active hepatitis, defined as: A (positive HA antigen or positive IgM); B (either positive HBs antigen or positive hepatitis B viral DNA test above the lower limit of detection of the assay); C (positive hepatitis C antibody result, and quantitative hepatitis C (HCV) ribonucleic acid (RNA) results greater than the lower limits of detection of the assay)
H. Participants who are unable to swallow normally or unable to take tablets and capsules. Predictable poor compliance with oral treatment
I. Participants with substantial MRI artifacts (e.g., related to localizer sequences, cardiac devices such as pacemakers, or other hardware) that render the lesion non-evaluable.
J. Severe allergy or reaction history to MRI contrast.
K. Participants currently undergoing or who have received treatment for another malignancy within the previous 6 months.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Aktywny komparator: chemoprevention therapy per investigator choice
For premenopausal women: 20 mg tamoxifen orally daily (standard dose) or 10 mg every other day (low dose). For postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, letrozole 2.5 mg daily, or anastrozole 1 mg daily; or reduced exemestane dosing: 25 mg 3X per week orally. For postmenopausal women who are not tolerating an AI, investigators can change them to the low dose (10 mg every other day) or standard dose (20 mg) of tamoxifen. There is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants may continue treatment for up to 5 years. |
For premenopausal women: 20 mg tamoxifen orally daily (standard dose) or 10 mg every other day (low dose). For postmenopausal women who are not tolerating an AI, investigators can change them to the low dose (10 mg every other day) or standard dose (20 mg) of tamoxifen. For postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, or reduced exemestane dosing: 25 mg 3 times per week orally For postmenopausal women: standard oral doses of AI of choice: letrozole 2.5 mg daily. For postmenopausal women: standard oral doses of AI of choice: anastrozole 1 mg daily. |
|
Eksperymentalny: Testosterone + Anastrazole (T+Ai)
White solid pellet for subcutaneous insertion consisting of 100mg Testosterone and 4mg Anastrazole, an aromatase inhibitor. A cylindrical pellet (4.5mm diameter, 6.35mm diameter) is inserted subcutaneously in the upper outer gluteal region or iliac fossa every 3 months, with treatment up to 36 months. There is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed for an additional 5 years. |
Investigational drug. Both pre- and post- menopausal subjects. 100mg testosterone in combination with 4mg anastrazole administered subcutaneously every 3 months for up to 3 years.
Inne nazwy:
|
|
Eksperymentalny: Elacestrant
Selective estrogen receptor degrader, Standard dose: 400mg PO with food once daily for treatment up to 36 months. Dose reduction of Elacestrant by up to 2 dose levels permitted depending on toxicity; 400 mg to 300 mg then 300 mg to 200 mg Participants requiring more than 2 dose reductions must discontinue treatment For patients on this arm there is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed by for an additional 5 years. |
Investigational drug. Both pre- and post- menopausal subjects. Elacestrant 400mg PO with food once daily up to 36 months. |
|
Eksperymentalny: Endoxifen
(Z)-endoxifen is the most active metabolite of the selective estrogen receptor modulator (SERM), tamoxifen. Standard dose: 10mg PO delayed release capsule of z-endoxifen once daily for treatment up to 36 months. same time with a glass of water either 1 hour before a meal or 2 hours after a meal and should not take with alcohol. For patients on this arm there is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed for an additional 5 years. |
Investigational drug. Both pre- and post- menopausal subjects. (z)-endoxifen 10mg delayed release capsule 1 hour before a meal or 2 hours after a meal once daily for up to 36 months. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Patients remaining on active surveillance at 7 months
Ramy czasowe: 7 months
|
Fraction of patients remaining on active surveillance at 7 months compared to control |
7 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
To determine whether novel endocrine therapy increases the fraction of patients who will be suitable for long-term active surveillance as measured by the fraction of patients deemed to be low-risk for invasive cancer at 6 months compared to control
Ramy czasowe: 6 months
|
Fraction of patients categorized as low risk by MRI after 6 months of treatment--Measured by cases demonstrating endocrine responsiveness (Determined based on lesion and background or lesion alone or lack of lesion and minimal background) |
6 months
|
|
To determine whether novel endocrine therapy increases the fraction of patients who will be suitable for long-term active surveillance as measured by the fraction of patients deemed to be low-risk for invasive cancer at 3 months compared to control
Ramy czasowe: 3 months
|
Fraction of patients categorized as low risk by MRI after 3 months of treatment--Measured by cases demonstrating endocrine responsiveness (Determined based on lesion and background or lesion alone or lack of lesion and minimal background) |
3 months
|
|
Associate rate of progression to Invasive Ductal Carcinoma (IDC) with risk categorization after 6 months of treatment at 3 years
Ramy czasowe: 3 years
|
Correlation of low-risk categorization at 6 months with subsequent rate of Invasive Ductal Cell Carcinoma progression at 3 years |
3 years
|
|
To assess the QoL impact of novel endocrine therapy compared to tamoxifen or Aromatase inhibitor (Ai) at standard or low dose using PROMIS and the FACT-ES and FACT-GP5 composite score compared to control
Ramy czasowe: 6 months
|
Fraction of patients experiencing Minimum Important Difference in overall QOL measured by PROP-R statistics (PROMIS) and FACT-ES (functional assessment of cancer therapy- endocrine symptoms) and FACT-GP5, a quality of life (QoL) assessment) |
6 months
|
|
For those with an identified lesion on MRI imaging, determine whether neoadjuvant endocrine therapy decreases lesion volume (qualitative, quantitative) and whether that corresponds to the biologic type of Ductal cell carcinoma In Situ (DCIS)
Ramy czasowe: 6 months
|
Rate of reduction in focal lesions (mass and non-mass enhancement (NME) at 6 months and Rate of reduction in focal lesions using automated Functional Tumor Volume |
6 months
|
|
To determine whether neoadjuvant endocrine therapy decreases automated background parenchymal enhancement (BPE and automated MRI density compared to Ai and Tamoxifen
Ramy czasowe: 6 months
|
% with contralateral reduction in qualitative and automated BPE and % reduction in contralateral breast density |
6 months
|
|
Determine adherence to active surveillance protocol
Ramy czasowe: 5 years
|
Time to discontinuation of therapy (Tolerability of therapy) will be measured, and Adherence rates on each regimen, as well as PROP-R, FACT-ES and FACT-GP5 score on each regimen will be measured. These assessments will be combined to evaluate efficacy and toxicity using a novel clinical benefit index. |
5 years
|
|
Change in artificial intelligence predicted risk based on mammography
Ramy czasowe: 5 years
|
Correlation of BPE change with agent and compare to quantitative imaging density |
5 years
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Assess Germ Line polygenic risk: assess correlation of detectable mutations with endocrine response and qualification for active surveillance at 7 months
Ramy czasowe: 7 months
|
evaluate influence of polygenic risk on endocrine response and suitability for Active Surveillance |
7 months
|
|
To evaluate outcomes stratified by immune and molecular subtype based upon multiplex immuno histochemistry (IHC) clustering analysis, and RPS expression array profiling
Ramy czasowe: 7 months
|
Response stratified by multiplex immune staining for Human Epidermal growth factor receptor-2 (HER2) isoforms and Response Predictive Subtypes (RPS) |
7 months
|
Współpracownicy i badacze
Śledczy
- Główny śledczy: Laura Esserman, MD, MBA, University of California, San Fancisco - Department of Surgery
- Główny śledczy: (Co-PI) Kelly Hewitt, MD, FACS, Huntsman Cancer Institute at the University of Utah
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Rak Piersi In Situ
- Nowotwory
- Nowotwory według typu histologicznego
- Nowotwory gruczołowe i nabłonkowe
- Rak gruczołowy
- Rak
- Nowotwory, przewodowe, zrazikowe i rdzeniaste
- Rak in situ
- Rak, wewnątrzprzewodowy, nienaciekający
- Hormony
- Hormony, substytuty hormonów i antagoniści hormonów
- Organiczne chemikalia
- Związki heterocykliczne, 1-ring
- Związki heterocykliczne
- Azole
- Węglowodory
- Węglowodory, cykliczne
- Węglowodory, aromatyczne
- Związki policykliczne
- Steroidy
- Związki sterownika
- Pochodne benzenu
- Nitryle
- Gonadalne hormony steroidowe
- Hormony gonadalne
- Androstennes
- Androstanes
- Triazole
- Stilbenes
- Związki benzylidenowe
- Androstenole
- Kongenerzy testosteronu
- Letrozol
- Anastrozol
- Testosteron
- Tamoksyfen
- przykład
- Elacestrant
- 4-hydroksy-n-desmetylotamoksyfen
Inne numery identyfikacyjne badania
- RECAST-DCIS
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .